<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255827</url>
  </required_header>
  <id_info>
    <org_study_id>NLG0105</org_study_id>
    <nct_id>NCT00255827</nct_id>
  </id_info>
  <brief_title>Vaccine Treatment for Surgically Resected Pancreatic Cancer</brief_title>
  <official_title>A Phase I/II Study of Algenpantucel-L (HyperAcute Pancreas) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewLink Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NewLink Genetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-phase study will determine the safety of treating patients with pancreatic cancer with
      the genetically engineered HyperAcute-Pancreatic cancer vaccine. It will establish the proper
      vaccine dose and will examine side effects and potential benefits of the treatment. The
      vaccine contains killed pancreatic cancer cells containing a mouse gene that causes the
      production of a foreign pattern of protein-sugars on the cell surface. It is hoped that the
      immune response to the foreign substance will stimulate the immune system to attack the
      patient's own cancer cells that have similar proteins without this sugar pattern, causing the
      tumor to remain stable or shrink.

      Patients 18 years of age or older with pancreatic cancer that has been surgically resected
      may be eligible for this study. Candidates will be screened with medical history and physical
      examination, blood tests, urinalysis, chest x-rays and CT scans. MRI, PET, and ultrasound
      scans may be obtained if needed.

      Participants will receive twelve vaccinations two weeks apart from each other. The vaccines
      will be injected under the skin, similar to the way a tuberculosis skin test is given. Phase
      I of the study will treat successive groups of patients with increasing numbers of the
      vaccine cells to evaluate side effects of the treatment and determine the optimum dose. Phase
      II will look for any beneficial effects of the vaccine given at the highest dose found to be
      safe in Phase I. Monthly blood samples will be drawn during the 6 months of vaccine
      treatment. In addition, patient follow-up visits will be scheduled every 2 months for the
      remaining first year (6 months) after vaccination and then every 3 months for the next 2
      years for the following tests and procedures to evaluate treatment response and side effects:

      Medical history and physical examination Blood tests X-rays and various scans (nuclear
      medicine/CT/MRI) FACT-Hep Assessment questionnaire to measure the impact of treatment on the
      patient's general well-being. The questionnaire is administered before beginning treatment,
      monthly during treatment, and during follow-up visits after completing the treatment. It
      includes questions on the severity of pancreatic cancer symptoms and the ability to perform
      normal activities of daily life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to statistics of the American Cancer Society, an estimated 31,000 individuals will
      be diagnosed with pancreatic cancer and 25,000 will die of the disease, making it the fifth
      leading cause of U.S. cancer deaths this year despite all current therapy. This protocol
      attempts to exploit an approach to pancreatic cancer immunotherapy using a naturally
      occurring barrier to xenotransplantation in humans in an attempt to vaccinate patients
      against their pancreatic cancer. The expression of the murine alpha (1,3)
      galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha
      (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids. These
      epitopes are the major target of the hyperacute rejection response that occurs when organs
      are transplanted from non-primate donor species into man. Human hosts often have pre-existing
      anti-alpha-gal antibodies that bind alpha-gal epitopes and lead to rapid activation of
      complement and cell lysis. The pre-existing anti-alpha-gal antibodies found in most
      individuals are thought to be due to exposure to alpha-gal epitopes that are naturally
      expressed on normal gut flora leading to chronic immunological stimulation. These antibodies
      may comprise up to 1% of serum IgG. In this Phase I/II trial, patients with surgically
      resected pancreatic cancer will undergo a series of twelve intradermal injections with a
      vaccine composed of irradiated allogeneic pancreatic cancer cell lines (HAPa-1 and HAPa-2)
      that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based
      retroviral vector expressing the murine alpha (1,3) GT gene. Endpoints of the study include
      determination of dose-limiting toxicity (DLT), maximum tolerated dose (MTD), tumor and
      immunological responses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the side effects, dose-limiting toxicity and maximum tolerated dose.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the rate of recurrence after treatment.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">7</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HyperAcute-Pancreatic Cancer Vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A histological diagnosis of adenocarcinoma or other exocrine carcinoma of the
             pancreas. The patient's pathology must be reviewed and confirmed by Northwestern
             University's Pathology Department.

          -  AJCC Stage I or II Pancreatic carcinoma. Patients must have undergone surgical
             resection for the tumor.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.

          -  Serum albumin greater than or equal to 2.5 gm/dL.

          -  Expected survival greater than or equal to 6 months.

          -  Subjects must have a negative serology for Hep B, C and HIV prior to entering study.

          -  All On-Study Tests must be less than or equal to Grade I toxicity for patient to be
             eligible for study, excluding serum LDH levels. PT, PTT must be less than or equal to
             1.5 x ULN except for patients who are on therapeutic anticoagulant therapy.

          -  Adequate organ function including:

        Marrow: hemoglobin greater than or equal to 10.0 gm/dL, absolute granulocyte count (AGC)
        greater than or equal to 1500/mm3, platelets greater than or equal to 100,000/mm3, absolute
        lymphocyte count greater than or equal to 475/mm3.

        Hepatic: serum total bilirubin less than or equal to 1.5 x ULN mg/dL, ALT (SGPT) and AST
        (SGOT) less than or equal to 2.5 x upper limit of normal (ULN).

        Renal: serum creatinine (sCr) less than or equal to 2.0 x ULN, or creatinine clearance
        (Ccr) greater than or equal to 30 mL/min.

          -  Prior therapy for pancreatic cancer that may include surgery and/or different
             neoadjuvant chemotherapy or adjuvant chemo-radiation regimens, or radiation therapy.
             Patients who undergo surgical resection and refuse chemotherapy or radiation therapy
             will be eligible.

          -  Patients must be greater than or equal to 4 weeks since surgery if treated with
             neoadjuvant therapy or greater than or equal to 4 weeks since conclusion of
             chemo-radiation if treated with post-operative adjuvant therapy and recovered from the
             toxicity of prior treatment to less than or equal to Grade I, exclusive of alopecia or
             fatigue.

          -  Patients must have the ability to understand the study, its inherent risks, side
             effects and potential benefits and be able give written informed consent to
             participate. Patients may not be consented by a durable power of attorney (DPA).

          -  All subjects of child producing potential must agree to use contraception or avoidance
             of pregnancy measures while enrolled on study and receiving the experimental product,
             and for one month after the last immunization.

        Exclusion Criteria:

          -  Age &lt;18-years-old.

          -  Active metastases.

          -  Hypercalcemia &gt; 2.9 mmol/L, unresponsive to standard therapy (e.g., I.V. hydration,
             diuretics, calcitonin or bisphosphonate therapy).

          -  Other malignancy within five years, unless the probability of recurrence of the prior
             malignancy is &lt;5%. Patient's curatively treated for squamous and basal cell carcinoma
             of the skin or patients with a history of malignant tumor in the past that have been
             disease free for at least five years are also eligible for this study.

          -  History of organ transplant or current active immunosuppressive therapy (such as
             cyclosporine, tacrolimus, etc.).

          -  Subjects taking systemic corticosteroid therapy for any reason are not eligible.
             Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who
             require systemic corticosteroids after beginning vaccination, will be removed from
             study.

          -  Significant or uncontrolled congestive heart failure (CHF), myocardial infarction or
             significant ventricular arrhythmias within the last six months.

          -  Active infection or antibiotics within 1-week prior to study, including unexplained
             fever (temp &gt; 38.1C).

          -  Autoimmune disease (e.g., systemic lupus erythematosis (SLE), rheumatoid arthritis
             (RA), etc.). Patients with a remote history of asthma or mild active asthma are
             eligible.

          -  Other serious medical conditions that may be expected to limit life expectancy to less
             than 2 years (e.g., liver cirrhosis) or a serious illness in medical opinion of the
             clinical investigator.

          -  Any condition, psychiatric or otherwise, that would preclude informed consent,
             consistent follow-up or compliance with any aspect of the study (e.g., untreated
             schizophrenia or other significant cognitive impairment, etc.).

          -  A known allergy to any component of the alpha(1,3)galactosyltransferase tumor vaccine
             or cell lines.

          -  Prior splenectomy.

          -  Pregnant or nursing women due to the unknown effects of vaccination on the developing
             fetus or newborn infant. (For patients with child bearing potential, a Î²HCG must be
             completed within 7 days of first vaccination).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Mulcahy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <name_title>Nicholas N. Vahanian, M.D., Chief Medical and Operations Officer</name_title>
    <organization>NewLink Genetics Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

